How increased biological understanding and advanced technology are generating new antibody-based modalities with exciting potential.

There are many players in pharmaceutical pricing, from drug manufacturers to PBMs and pharmacies. Who should take the lead?

Endogena Therapeutics CEO Matthias Steger discusses fast track FDA approval for EA-2353, a new drug for the treatment of retinitis pigmentosa

An insight into the research fuelling developments for universal cancer immunotherapies

Understanding the role of microbial fermentation in the production of mRNA vaccines.

Hall Gregg, Chief Portfolio Officer at the Pistoia Alliance, discusses the transformative power of collaboration, innovation, and diversification

We ask an expert for their top tips for ensuring outsourcing goes smoothly.

How fucosylation-deficient CHO cell hosts can help enhance the potency of monoclonal antibody-based biotherapeutics

When it comes to influenza, chicken egg-based vaccines have achieved much, but emerging approaches are ready to fly the coop.

What can science learn from patients, and how can patients benefit from being in control of their own health?